Rhythm Pharmaceuticals Reports Strong Q3 2025 Results with $51.3M IMCIVREE Revenue and December FDA Decision Pending
核心洞察
Rhythm Pharmaceuticals achieved $51.3 million in global IMCIVREE sales for Q3 2025, representing a 6% sequential increase driven primarily by growth in Bardet-Biedl syndrome (搜索) patients.
The FDA has set a December 20, 2025 PDUFA goal date for the company's supplemental new drug application seeking approval of setmelanotide for acquired hypothalamic obesity (搜索) treatment.
A German observational study demonstrated that setmelanotide therapy improved measures of metabolic dysfunction-associated steatotic liver disease (搜索) and kidney function in Bardet-Biedl syndrome (搜索) patients.
Rhythm Pharmaceuticals delivered strong third quarter 2025 financial results, reporting $51.3 million in global net product revenue from IMCIVREE (setmelanotide), marking a 6% sequential increase from the second quarter of 2025. The commercial-stage biopharmaceutical company, focused on rare neuroendocrine diseases, continues to build momentum as it approaches a critical FDA decision for expanded indications.
"Rhythm delivered continued momentum during the third quarter, highlighted by the FDA acceptance of our supplemental new drug application (sNDA) for acquired hypothalamic obesity (搜索) (HO) and steady growth from our Bardet-Biedl syndrome (搜索) (BBS) commercial efforts," said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm.
Strong Commercial Performance Driven by BBS Growth
The third quarter revenue growth was primarily driven by increased patient numbers and sales of IMCIVREE for treating patients with Bardet-Biedl syndrome (搜索). U.S. revenue reached $38.2 million, representing 74% of total product revenue and a 19% sequential increase. International revenue totaled $13.1 million, though this was affected by a one-time $3.2 million charge related to pricing adjustments for the French early access program and variability in named patient sales ordering patterns.
IMCIVREE, an MC4R (搜索) agonist, is currently approved by the FDA to reduce excess body weight and maintain weight reduction in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (搜索) or genetically confirmed POMC (搜索), PCSK1 (搜索), or LEPR (搜索) deficiency.
Critical FDA Decision Approaches
The FDA has accepted Rhythm's supplemental new drug application for setmelanotide in acquired hypothalamic obesity (搜索), granting Priority Review with a PDUFA goal date of December 20, 2025. The European Medicines Agency (搜索) has also validated the Type II variation submission for the same indication, expanding potential market opportunities.
Clinical Evidence Continues to Build
Recent clinical developments strengthen setmelanotide's therapeutic profile. Researchers at the University Hospital Essen published results from a prospective observational study in the Journal of Clinical Endocrinology & Metabolism showing that setmelanotide treatment was associated with improvement in measures of metabolic dysfunction-associated steatotic liver disease (搜索) (MASLD) and kidney function in patients with BBS. All 26 patients in the study had MASLD at baseline, and after six months of setmelanotide treatment, more than 80% achieved either resolution of MASLD or stabilization at grade S1.
Four abstracts have been accepted for presentation at ObesityWeek 2025, including an oral presentation on "Efficacy of Setmelanotide in Patients with Acquired HO Previously or Concurrently on GLP-1 Therapy" and poster presentations covering cardiometabolic results, patient-reported experiences, and genetic variant identification in early-onset obesity.
Robust Pipeline Progress
Rhythm expects to report preliminary results from its Phase 2 trial evaluating setmelanotide in Prader-Willi syndrome (搜索) in the fourth quarter of 2025. The company also anticipates completing enrollment in its Phase 1, Part C trial evaluating weekly MC4R (搜索) agonist RM-718 in patients with acquired hypothalamic obesity (搜索) in the first quarter of 2026.
Additional upcoming milestones include topline data from the 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired hypothalamic obesity (搜索) and the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R (搜索) pathway diseases, both expected in the first quarter of 2026.
Financial Position and Outlook
As of September 30, 2025, Rhythm maintained a strong cash position with approximately $416.1 million in cash, cash equivalents and short-term investments, compared to $320.6 million at the end of 2024. The company updated its 2025 financial guidance, anticipating approximately $295 million to $315 million in Non-GAAP Operating Expenses.
Research and development expenses increased to $46.0 million in the third quarter compared to $37.9 million in the prior year, primarily due to increased headcount and stock-based compensation. Selling, general and administrative expenses rose to $52.4 million from $35.4 million, reflecting expanded business operations and marketing investments.
Based on current operating plans, Rhythm expects its cash position will fund planned operations for at least 24 months, providing financial stability as the company advances its melanocortin-4 receptor (搜索) pathway pipeline and awaits the critical FDA decision on acquired hypothalamic obesity (搜索).